Cargando…

Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent

Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pahljina, Christian, Sarny, Stephanie, Hoeflechner, Lukas, Falb, Thomas, Schliessleder, Gernot, Lindner, Marlene, Ivastinovic, Domagoj, Mansouri, Kaweh, Lindner, Ewald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225126/
https://www.ncbi.nlm.nih.gov/pubmed/35743517
http://dx.doi.org/10.3390/jcm11123450
_version_ 1784733542957187072
author Pahljina, Christian
Sarny, Stephanie
Hoeflechner, Lukas
Falb, Thomas
Schliessleder, Gernot
Lindner, Marlene
Ivastinovic, Domagoj
Mansouri, Kaweh
Lindner, Ewald
author_facet Pahljina, Christian
Sarny, Stephanie
Hoeflechner, Lukas
Falb, Thomas
Schliessleder, Gernot
Lindner, Marlene
Ivastinovic, Domagoj
Mansouri, Kaweh
Lindner, Ewald
author_sort Pahljina, Christian
collection PubMed
description Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwent phacoemulsification with the Xen gel stent at the Medical University of Graz, Austria. Quality of life was assessed using the German version of the Glaucoma Symptoms Scale (GSS)—questionnaire. Patients were also asked whether the operation reduced glaucoma medications and to indicate their overall satisfaction from 1 (totally discontented) up to 10 (totally contented). Questionnaires of 80 patients were evaluated. A total of 36 patients (45.0%) reported a reduction in glaucoma medications. Three items of the GSS were significantly better in patients who needed fewer glaucoma medications after the operation (“hard to see in daylight”, 75.0 ± 31.1 vs. 57.7 ± 39.1, p = 0.035; “hard to see in dark places”, 81.1 ± 28.7 vs. 54.9 ± 41.2, p = 0.002; and “halos around lights”, 88.3 ± 25.9 vs. 68.8 ± 38.6, p = 0.002). Patient satisfaction was significantly higher when the procedure led to a reduction in glaucoma medication (8.3 ± 2.0 vs. 6.8 ± 3.1; p = 0.034). The reported quality of life and patient satisfaction were significantly better when phacoemulsification with the Xen gel stent reduced the number of glaucoma medications needed.
format Online
Article
Text
id pubmed-9225126
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92251262022-06-24 Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent Pahljina, Christian Sarny, Stephanie Hoeflechner, Lukas Falb, Thomas Schliessleder, Gernot Lindner, Marlene Ivastinovic, Domagoj Mansouri, Kaweh Lindner, Ewald J Clin Med Article Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwent phacoemulsification with the Xen gel stent at the Medical University of Graz, Austria. Quality of life was assessed using the German version of the Glaucoma Symptoms Scale (GSS)—questionnaire. Patients were also asked whether the operation reduced glaucoma medications and to indicate their overall satisfaction from 1 (totally discontented) up to 10 (totally contented). Questionnaires of 80 patients were evaluated. A total of 36 patients (45.0%) reported a reduction in glaucoma medications. Three items of the GSS were significantly better in patients who needed fewer glaucoma medications after the operation (“hard to see in daylight”, 75.0 ± 31.1 vs. 57.7 ± 39.1, p = 0.035; “hard to see in dark places”, 81.1 ± 28.7 vs. 54.9 ± 41.2, p = 0.002; and “halos around lights”, 88.3 ± 25.9 vs. 68.8 ± 38.6, p = 0.002). Patient satisfaction was significantly higher when the procedure led to a reduction in glaucoma medication (8.3 ± 2.0 vs. 6.8 ± 3.1; p = 0.034). The reported quality of life and patient satisfaction were significantly better when phacoemulsification with the Xen gel stent reduced the number of glaucoma medications needed. MDPI 2022-06-15 /pmc/articles/PMC9225126/ /pubmed/35743517 http://dx.doi.org/10.3390/jcm11123450 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pahljina, Christian
Sarny, Stephanie
Hoeflechner, Lukas
Falb, Thomas
Schliessleder, Gernot
Lindner, Marlene
Ivastinovic, Domagoj
Mansouri, Kaweh
Lindner, Ewald
Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
title Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
title_full Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
title_fullStr Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
title_full_unstemmed Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
title_short Glaucoma Medication and Quality of Life after Phacoemulsification Combined with a Xen Gel Stent
title_sort glaucoma medication and quality of life after phacoemulsification combined with a xen gel stent
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225126/
https://www.ncbi.nlm.nih.gov/pubmed/35743517
http://dx.doi.org/10.3390/jcm11123450
work_keys_str_mv AT pahljinachristian glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT sarnystephanie glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT hoeflechnerlukas glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT falbthomas glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT schliessledergernot glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT lindnermarlene glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT ivastinovicdomagoj glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT mansourikaweh glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent
AT lindnerewald glaucomamedicationandqualityoflifeafterphacoemulsificationcombinedwithaxengelstent